Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension

Study Identifier
210669-013
CT.gov Identifier
NCT01291108
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Glaucoma - Open Angle
  • Ocular Hypertension
    • Study Drug
  • AGN-210669
  • bimatoprost
  • bimatoprost vehicle
    • Phase
    Phase 2
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Diagnosis of primary open-angle glaucoma or ocular hypertension in each eye * Requires bilateral treatment with an IOP-lowering medication * Best corrected visual acuity of 20/100 or better in each eye
    Exclusion Criteria:
    * Use of oral, intramuscular, intravenous or topical ophthalmic corticosteroids within 2 months * Inability to fast for up to 10 hours * Prior refractive laser surgery (eg, LASIK, radial keratectomy, photorefractive keratectomy) * Intraocular surgery or IOP-lowering laser surgery (eg, laser trabeculoplasty) within 6 months * Current or anticipated use of artificial tears or any ocular medications aside from study medications during study * Anticipated wearing of contact lenses during study

    Protocol Summary

    This study will evaluate the safety and efficacy of AGN-210669 ophthalmic solution compared with bimatoprost ophthalmic solution (Lumigan®) as monotherapy and adjunctive therapy in patients with primary open-angle glaucoma or ocular hypertension.

    Study Locations

    Location
    Status
    Location
    Austin, Texas, United States
    Status
    Not applicable